Thermo Fisher Scientific (TMO) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $218.90B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Marc N. Casper |
| IPO Date | 1980-03-17 | CAGR | 13.66% |
| Employees | 125,000 | Website | www.thermofisher.com |
| Div. Yield | 0.14% | Payout Ratio | 9% |
| Buy Back Yield | 1.1% | Total Yield | 1.24% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $240.44B | P/E | 25.43 | Forward P/E | 21.28 | PEG | 3.37 |
| P/S | 9.77 | P/B | 8.6 | P/CF | 50.23 | P/FCF | 61.96 |
| Sales | $46.34B | Sales 1Y | 7.23% | Sales 3Y | 6.46% | Sales 5Y | 21.14% |
| EPS | $23.16 | EPS 1Y | 7.58% | EPS 3Y | 27.15% | EPS 5Y | -13.82% |
| Sales QoQ | 8.99% | EPS QoQ | 5.64% | Sales QoQ Avg | 2.84% | EPS QoQ Avg | 3.11% |
| Gross Margin | 40.37% | Operating Margin | 17.69% | Profit Margin | 15.06% | ROCE | 8.35% |
| ROA | 6% | ROE | 13% | Altman Z Score | 2.99 | Piotroski Score | 6 |
| Current Ratio | 1.55 | Quick Ratio | 1.18 | Cash Ratio | 0.27 | Op. CF Ratio | 0.14 |
| Debt/Equity | 0.81 | Debt/Assets | 0.38 | Lt Debt/Equity | 0.74 | Lt Debt/Cap. | 0.43 |
| Intrst Cov. | 5.59 | Inventory Turnover | 4.91 | Asset Turnover | 0.41 | Receivables Turnover | 4.9 |
| Enterprise Value | $240.44B | P/E Ratio | 25.43 |
| Forward P/E | 21.28 | PEG Ratio | 3.37 |
| P/S Ratio | 9.77 | P/B Ratio | 8.6 |
| P/CF Ratio | 50.23 | P/FCF Ratio | 61.96 |
| EPS | $23.16 | EPS Growth 1Y | 7.58% |
| EPS Growth 3Y | 27.15% | EPS Growth 5Y | -13.82% |
| Revenue Growth 1Y | 7.23% | Gross Margin | 0.4% |
| Operating Margin | 0.18% | Profit Margin | 0.15% |
| ROE | 0.13% | ROA | 0.06% |
| ROCE | 0.08% | Current Ratio | 1.55 |
| Quick Ratio | 1.18 | Cash Ratio | 0.27 |
| Debt/Equity | 0.81 | Interest Coverage | 5.59 |
| Altman Z Score | 2.99 | Piotroski Score | 6 |
Thermo Fisher Scientific (TMO) valuation & financials
Thermo Fisher Scientific (TMO) has a market capitalization of $218.90B and trades at a price-to-earnings ratio of 25.4. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Thermo Fisher Scientific's revenue grew +7.2% over the last year.
Thermo Fisher Scientific's next earnings report is scheduled for October 28, 2026 before market open; analysts estimate EPS of $6.40. Check the earnings calendar to see all companies reporting this week.
Thermo Fisher Scientific (TMO) — frequently asked questions
When does Thermo Fisher Scientific (TMO) report earnings next?
Thermo Fisher Scientific is expected to report earnings on October 28, 2026 before market open. Analysts estimate EPS of $6.40.
What is Thermo Fisher Scientific's market cap?
Thermo Fisher Scientific (TMO) has a market capitalization of $218.90B.
What is TMO's P/E ratio?
Thermo Fisher Scientific trades at a price-to-earnings ratio of 25.4, with trailing twelve-month EPS of $23.16.
How fast is Thermo Fisher Scientific growing?
Thermo Fisher Scientific's revenue grew +7.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)